Skip to Main Content
Qurgen Qurgen
Menu Button

Oct. 14, 2024

Brand Icon
On Oct 14, 2024, the China CDE officially approved the IND application of SON-DP Phase I study, submitted by Fuent Pharmaceutcal Co., Ltd. (Qurgen’s China subsidiary), with the CDE acceptance number: CXSL2400508.

Recent important events

Mar. 2026
Qurgen announced that a late-stage of ocular melanoma patient from the ongoing Qurgen clinical trial...
Learn More
Jan. 13, 2026
Dr. Chai Yan officially Joined Qurgen/Fuent (The Qurgen’s China subsidiary) as Senior Vice President of...
Learn More